West Coast Financial LLC Sells 696 Shares of Edwards Lifesciences Co. (NYSE:EW)

West Coast Financial LLC lowered its stake in Edwards Lifesciences Co. (NYSE:EWFree Report) by 0.5% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 142,948 shares of the medical research company’s stock after selling 696 shares during the quarter. Edwards Lifesciences accounts for 1.7% of West Coast Financial LLC’s portfolio, making the stock its 14th largest position. West Coast Financial LLC’s holdings in Edwards Lifesciences were worth $13,660,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Riverview Trust Co purchased a new stake in Edwards Lifesciences in the first quarter worth approximately $34,000. Central Valley Advisors LLC boosted its holdings in Edwards Lifesciences by 10.9% in the first quarter. Central Valley Advisors LLC now owns 13,905 shares of the medical research company’s stock worth $1,329,000 after purchasing an additional 1,367 shares during the last quarter. Jacobs & Co. CA boosted its holdings in Edwards Lifesciences by 1.9% in the first quarter. Jacobs & Co. CA now owns 112,781 shares of the medical research company’s stock worth $10,777,000 after purchasing an additional 2,116 shares during the last quarter. Harbor Investment Advisory LLC boosted its holdings in Edwards Lifesciences by 2.9% in the first quarter. Harbor Investment Advisory LLC now owns 14,025 shares of the medical research company’s stock worth $1,340,000 after purchasing an additional 396 shares during the last quarter. Finally, Global Assets Advisory LLC purchased a new stake in Edwards Lifesciences in the first quarter worth approximately $3,053,000. Hedge funds and other institutional investors own 79.46% of the company’s stock.

Insider Transactions at Edwards Lifesciences

In other news, VP Donald E. Bobo, Jr. sold 5,000 shares of the business’s stock in a transaction dated Wednesday, June 12th. The shares were sold at an average price of $87.54, for a total value of $437,700.00. Following the sale, the vice president now directly owns 46,936 shares in the company, valued at approximately $4,108,777.44. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. In related news, Director Michael A. Mussallem sold 29,350 shares of Edwards Lifesciences stock in a transaction dated Thursday, April 4th. The shares were sold at an average price of $92.42, for a total transaction of $2,712,527.00. Following the completion of the transaction, the director now directly owns 4,486 shares of the company’s stock, valued at approximately $414,596.12. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, VP Donald E. Bobo, Jr. sold 5,000 shares of Edwards Lifesciences stock in a transaction dated Wednesday, June 12th. The stock was sold at an average price of $87.54, for a total transaction of $437,700.00. Following the transaction, the vice president now directly owns 46,936 shares of the company’s stock, valued at $4,108,777.44. The disclosure for this sale can be found here. Insiders have sold a total of 127,104 shares of company stock worth $11,267,464 in the last three months. Insiders own 1.27% of the company’s stock.

Edwards Lifesciences Price Performance

NYSE EW traded up $0.42 on Tuesday, reaching $90.59. The company had a trading volume of 1,041,649 shares, compared to its average volume of 3,397,699. The company has a quick ratio of 2.67, a current ratio of 3.75 and a debt-to-equity ratio of 0.08. The stock has a market capitalization of $54.59 billion, a PE ratio of 38.86, a price-to-earnings-growth ratio of 3.33 and a beta of 1.11. The firm’s 50 day moving average price is $87.48 and its 200 day moving average price is $84.80. Edwards Lifesciences Co. has a 12 month low of $60.57 and a 12 month high of $96.12.

Edwards Lifesciences (NYSE:EWGet Free Report) last announced its quarterly earnings results on Thursday, April 25th. The medical research company reported $0.66 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.64 by $0.02. The company had revenue of $1.60 billion for the quarter, compared to the consensus estimate of $1.58 billion. Edwards Lifesciences had a net margin of 23.01% and a return on equity of 22.86%. As a group, equities analysts predict that Edwards Lifesciences Co. will post 2.77 earnings per share for the current year.

Wall Street Analyst Weigh In

Several research analysts have recently weighed in on EW shares. Piper Sandler lifted their price target on shares of Edwards Lifesciences from $85.00 to $88.00 and gave the stock a “neutral” rating in a research note on Friday, April 26th. Barclays lifted their price target on shares of Edwards Lifesciences from $100.00 to $101.00 and gave the stock an “overweight” rating in a research note on Tuesday, May 7th. Citigroup upgraded shares of Edwards Lifesciences from a “neutral” rating to a “buy” rating and lifted their price target for the stock from $98.00 to $105.00 in a research note on Wednesday, May 22nd. Bank of America upgraded shares of Edwards Lifesciences from a “neutral” rating to a “buy” rating in a research note on Thursday, March 7th. Finally, StockNews.com cut shares of Edwards Lifesciences from a “buy” rating to a “hold” rating in a research note on Tuesday, June 18th. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating and fourteen have given a buy rating to the company’s stock. Based on data from MarketBeat, Edwards Lifesciences has a consensus rating of “Moderate Buy” and an average price target of $95.06.

Read Our Latest Report on Edwards Lifesciences

Edwards Lifesciences Profile

(Free Report)

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.

Read More

Institutional Ownership by Quarter for Edwards Lifesciences (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.